285 related articles for article (PubMed ID: 33675416)
1. Prognostic significance of total plasma cell-free DNA level and androgen receptor amplification in castration-resistant prostate cancer.
Kubota Y; Hatakeyama S; Yoneyama T; Yoneyama MS; Hamano I; Konishi S; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Ohyama C
World J Urol; 2021 Sep; 39(9):3265-3271. PubMed ID: 33675416
[TBL] [Abstract][Full Text] [Related]
2. Copy Number Gain in Androgen Receptors Predicts the Poor Prognosis in Japanese Castration-resistant Prostate Cancer.
Sakamoto S; Ando K; Pae S; Zhao X; Sakai K; Sato K; Saito S; Yamada Y; Rii J; Goto Y; Sazuka T; Imamura Y; Anzai N; Akakura K; Nishio K; Ichikawa T
Anticancer Res; 2024 Feb; 44(2):639-647. PubMed ID: 38307556
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer.
Sumiyoshi T; Mizuno K; Yamasaki T; Miyazaki Y; Makino Y; Okasho K; Li X; Utsunomiya N; Goto T; Kobayashi T; Terada N; Inoue T; Kamba T; Fujimoto A; Ogawa O; Akamatsu S
Sci Rep; 2019 Mar; 9(1):4030. PubMed ID: 30858508
[TBL] [Abstract][Full Text] [Related]
4. Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients.
Kohli M; Li J; Du M; Hillman DW; Dehm SM; Tan W; Carlson R; Campion MB; Wang L; Wang L; Zhang H; Zhang P; Kilari D; Huang CC; Wang L
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):411-418. PubMed ID: 29858592
[TBL] [Abstract][Full Text] [Related]
5. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
[TBL] [Abstract][Full Text] [Related]
6. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
Linder A; Larsson K; Welén K; Damber JE
Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
[TBL] [Abstract][Full Text] [Related]
7. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
Azad AA; Volik SV; Wyatt AW; Haegert A; Le Bihan S; Bell RH; Anderson SA; McConeghy B; Shukin R; Bazov J; Youngren J; Paris P; Thomas G; Small EJ; Wang Y; Gleave ME; Collins CC; Chi KN
Clin Cancer Res; 2015 May; 21(10):2315-24. PubMed ID: 25712683
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients.
Hendriks RJ; Dijkstra S; Smit FP; Vandersmissen J; Van de Voorde H; Mulders PFA; van Oort IM; Van Criekinge W; Schalken JA
Prostate; 2018 Apr; 78(5):336-342. PubMed ID: 29330943
[TBL] [Abstract][Full Text] [Related]
9. Androgen-receptor splice variant-7-positive prostate cancer: a novel molecular subtype with markedly worse androgen-deprivation therapy outcomes in newly diagnosed patients.
Li H; Wang Z; Xiao W; Yan L; Guan W; Hu Z; Wu L; Huang Q; Wang J; Xu H; Zhang X; Ye Z
Mod Pathol; 2018 Jan; 31(1):198-208. PubMed ID: 29076496
[TBL] [Abstract][Full Text] [Related]
10. Impact of androgen receptor alterations on cell-free DNA genomic profiling on survival outcomes in metastatic castration-resistant prostate cancer.
Tripathi N; Thomas VM; Sayegh N; Gebrael G; Chigarira B; Jo Y; Li H; Sahu KK; Nussenzveig R; Nordblad B; Swami U; Agarwal N; Maughan BL
Prostate; 2023 Dec; 83(16):1602-1609. PubMed ID: 37644774
[TBL] [Abstract][Full Text] [Related]
11. Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.
Fettke H; Kwan EM; Docanto MM; Bukczynska P; Ng N; Graham LK; Mahon K; Hauser C; Tan W; Wang XH; Zhao Z; Zheng T; Zhou K; Du P; Yu J; Huang Y; Jia S; Kohli M; Horvath LG; Azad AA
Eur Urol; 2020 Aug; 78(2):173-180. PubMed ID: 32487321
[TBL] [Abstract][Full Text] [Related]
12. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
[TBL] [Abstract][Full Text] [Related]
13. AR gene rearrangement analysis in liquid biopsies reveals heterogeneity in lethal prostate cancer.
Daniel M; Knutson TP; Sperger JM; Li Y; Singh A; Stahlfeld CN; Passow C; Auch B; Lang JM; Dehm SM
Endocr Relat Cancer; 2021 Aug; 28(9):645-655. PubMed ID: 34280123
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Impact of Total Plasma Cell-free DNA Concentration in Androgen Receptor Pathway Inhibitor-treated Metastatic Castration-resistant Prostate Cancer.
Fettke H; Kwan EM; Bukczynska P; Ng N; Nguyen-Dumont T; Southey MC; Davis ID; Mant A; Parente P; Pezaro C; Hauser C; Azad AA
Eur Urol Focus; 2021 Nov; 7(6):1287-1291. PubMed ID: 32739405
[TBL] [Abstract][Full Text] [Related]
15. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
16. [ARV-7: A biomarker for the treatment of metastatic castration-resistant prostate cancer].
Chen ZY; Dong Q; Liu LR; Wei Q
Zhonghua Nan Ke Xue; 2019 Feb; 25(2):172-176. PubMed ID: 32216207
[TBL] [Abstract][Full Text] [Related]
17. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
[TBL] [Abstract][Full Text] [Related]
18. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
19. Standardization of CTC AR-V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression.
Tommasi S; Pilato B; Carella C; Lasorella A; Danza K; Vallini I; De Summa S; Naglieri E
Prostate; 2019 Jan; 79(1):54-61. PubMed ID: 30141201
[TBL] [Abstract][Full Text] [Related]
20. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.
Lallous N; Volik SV; Awrey S; Leblanc E; Tse R; Murillo J; Singh K; Azad AA; Wyatt AW; LeBihan S; Chi KN; Gleave ME; Rennie PS; Collins CC; Cherkasov A
Genome Biol; 2016 Jan; 17():10. PubMed ID: 26813233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]